Verici Logo

Result of AGM and voting results

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at the
Annual General Meeting (“AGM”) held earlier today, all resolutions were duly passed.
The voting results of the AGM were as follows:

In Favour Against Withheld
Resolution Votes % Votes % Votes
1 62,212,695 100 0 0 0
2 62,212,118 100 577 0 0
3 62,212,545 100 0 0 150
4 52,879,826 85 9,332,869 15 0
5 51,490,878 83 10,720,067 17 1,750



Verici Dx
Sara Barrington, CEO
Julian Baines, Chairman
Via Walbrook PR

N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell / Kailey Aliyar / Tom Salvesen
Tel: 020 7496 3000
Walbrook PR Limited
Paul McManus / Sam Allen

Tel: 020 7933 8780 or
Mob: 07980 541 893 /
07502 558 258



About Verici Dx plc

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.